Immunotherapy for stage II or III rectal cancer
Part of Cancer, Digestive system, Immune system & allergy clinical trials.
This trial tests a new combination of two immunotherapy drugs (called anti-PD-1 and anti-CTLA-4) for people with stage II or III rectal cancer. The goal is to see if these drugs can shrink the tumor and improve outcomes before surgery or as part of the main treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old and in generally good health
- You have a type of rectal cancer called rectal adenocarcinoma (confirmed by a biopsy)
- Your cancer is at a stage that hasn't spread too far (called stage II or III), and the tumor is within reach of the anus (no more than 12 cm from the anal verge)
- You have not had chemotherapy, radiation, or immunotherapy before for this cancer
- You do not have serious heart, lung, liver, or kidney problems, or an autoimmune disease
- You are willing to give tissue and blood samples for research and to follow the study plan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a shorter course of radiation therapy that avoids lymph nodes, followed by an immunotherapy drug, for patients with stage II or III rectal cancer that has not spread. It aims to improve outcomes while reducing side effects.
This trial combines a special type of radiation (MRI-guided adaptive radiotherapy) with an immunotherapy drug (PD-1 antibody) and chemotherapy (CAPOX) for locally advanced rectal cancer. The goal is to see if this combination can improve treatment outcomes.
This trial studies giving long-course radiation and chemotherapy before surgery, plus an immunotherapy medicine (PD-1) to help the tumor shrink more. It’s for people with stage II or III rectal cancer that has not spread to distant organs.
This trial tests a treatment plan involving radiation, chemotherapy, and an immunotherapy drug (a PD-1 inhibitor) for people with a specific type of high-risk rectal cancer. The goal is to see if this combination helps shrink the tumor before surgery.
This trial tests a combination of radiation, chemotherapy, and immunotherapy drugs before surgery for people with locally advanced rectal cancer. The goal is to shrink the tumor and improve outcomes for patients with higher-risk disease.
This trial tests a shorter course of radiation combined with chemotherapy and immunotherapy to treat mid- to low rectal cancer. The goal is to potentially improve outcomes while reducing side effects.
Hear when a new Locally Advanced Rectal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.